# CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease

> **NCT07193667** · NA · RECRUITING · sponsor: **ShenZhen Cell Valley** · enrollment: 3 (estimated)

## Conditions studied

- Relapsed/Refractory Autoimmune Diseases

## Interventions

- **DRUG:** CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases

## Key facts

- **NCT ID:** NCT07193667
- **Lead sponsor:** ShenZhen Cell Valley
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193667, "CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07193667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*